Clinical Trial Update: A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors [Phase 1]

View source ↗

Summary

BeiGene is conducting a Phase 1 safety study to evaluate different doses of BG-68501 in participants with various advanced-stage cancers, and recruitment is ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Endometrial Cancer
• Gastric Cancer
• Ovarian Cancer
• Prostate Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• BG-68501

Snippet

Sponsor: BeiGene | Conditions: Breast Cancer, Small Cell Lung Cancer | Phase 1 | Status: RECRUITING